摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,7-二氮杂螺[2.5]辛烷双盐酸盐 | 145122-56-1

中文名称
4,7-二氮杂螺[2.5]辛烷双盐酸盐
中文别名
4,7-氮杂螺[2.5]辛烷二盐酸盐;4,7-二氮杂螺[2.5]辛烷二盐酸盐
英文名称
4,7-Diazaspiro[2.5]octane dihydrochloride
英文别名
4,7-diazaspiro[2.5]octane;dihydrochloride
4,7-二氮杂螺[2.5]辛烷双盐酸盐化学式
CAS
145122-56-1
化学式
C6H14Cl2N2
mdl
——
分子量
185.09
InChiKey
MWCKCAQLDIGIMK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.56
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    24.1
  • 氢给体数:
    4
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:aa7bc85157de871cdff87b7a10625da3
查看

制备方法与用途

用途

4,7-二氮杂螺[2.5]辛烷双盐酸盐用作研究用化合物。

文献信息

  • [EN] TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROPYRIDOPYRIDINE ET TÉTRAHYDROPYRIDOPYRIMIDINE ET UTILISATION DE CEUX-CI EN TANT QUE MODULATEURS DE RÉCEPTEUR C5A
    申请人:NOVARTIS AG
    公开号:WO2013016197A1
    公开(公告)日:2013-01-31
    The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了一种化合物I的化合物:(I)本发明的化合物的制备方法及其治疗用途。本发明还提供了一种药理活性剂的组合和药物组合物。
  • [EN] COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UNE AMYOTROPHIE SPINALE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2016184832A1
    公开(公告)日:2016-11-24
    The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    本发明提供了如下式(I)中的化合物,其中A、X、Y、R1和R2如本文所述,以及其药学上可接受的盐。此外,本发明涉及制造如式(I)中的化合物,包括含有它们的药物组合物以及它们作为药物的用途。
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    申请人:AbbVie Inc.
    公开号:US20150218102A1
    公开(公告)日:2015-08-06
    Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , R 2 , and R 3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na v 1.7 and/or Na v 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    公式(I)的化合物及其药用可接受的盐、酯、酰胺或放射标记形式,其中R1、R2和R3如规范中所定义,可用于治疗由电压门控通道,例如Nav1.7和/或Nav1.8,预防或缓解的疾病或疾病。公开了制备这些化合物的方法。还公开了公式(I)的化合物的药物组合物,以及使用这些化合物和组合物的方法。
  • [EN] COMPOUNDS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2017081111A1
    公开(公告)日:2017-05-18
    The present invention provides compounds of formula (I) (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof for use in the treatment, prevention and/or delay of progression of amyotrophic lateral sclerosis (ALS). Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    本发明提供了如下式(I)的化合物(I)其中A、R1、R2和R3如本文所述,以及其在治疗、预防和/或延缓肌萎缩侧索硬化症(ALS)进展方面的药用盐。此外,本发明涉及如何制造如上式(I)的化合物、包含它们的药物组合物以及它们作为药物的用途。
  • COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
    申请人:Hoffmann-La Roche Inc.
    公开号:US20190315773A1
    公开(公告)日:2019-10-17
    The present invention provides compounds of formula (I) wherein A, R 1 , R 2 and R 3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    本发明提供了以下式(I)的化合物,其中A、R1、R2和R3如本文所述,并且其药学上可接受的盐。此外,本发明涉及制备上述式(I)化合物,包括它们的药物组合物以及它们作为药物的用途。
查看更多